Latest News

  • Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer Read More
  • Alkermes to Take Part in Stifel's 3rd Annual CNS Day Read More
  • Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy Read More
  • Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

COVID-19

Response to Current Events
COVID-19 Read Our Response